Department of Medical Zoology, School of Basic Medicine, Lanzhou University, Lanzhou, China.
The Reproductive Medicine Hospital of the First Hospital of Lanzhou University, Lanzhou, Gansu, China.
J Assist Reprod Genet. 2023 Jan;40(1):19-32. doi: 10.1007/s10815-022-02674-y. Epub 2022 Dec 12.
Modeling methods for busulfan-induced oligoasthenozoospermia are controversial. We aimed to systematically review the modeling method of busulfan-induced oligospermia and asthenozoospermia, and analyze changes in various evaluation indicators at different busulfan doses over time.
We searched the Cochrane Library, PubMed databases, Web of Science, the Chinese National Knowledge Infrastructure, and the Chinese Biomedical Literature Service System until April 9, 2022. Animal experiments of busulfan-induced spermatogenesis dysfunction were included and screened. The model mortality and parameters of the evaluation indicators were subjected to meta-analysis.
Twenty-nine animal studies were included (control/model: 669/1829). The mortality of mice increased with busulfan dose. Significant spermatogenesis impairment occurred within 5 weeks, regardless of busulfan dose (10-40 mg/kg). Testicular weight (weighted mean difference [WMD]: - 0.04, 95% CI: - 0.05, - 0.03), testicular index (WMD: - 2.10, 95% CI: - 2.43, - 1.76), and Johnsen score (WMD: - 4.67, 95% CI: - 5.99, - 3.35) were significantly decreased. The pooled sperm counts of the model group were reduced by 32.8 × 10/ml (WMD: - 32.8, 95% CI: - 44.34, - 21.28), and sperm motility decreased by 37% (WMD: - 0.37, 95% CI: - 0.47, - 0.27). Sperm counts decreased slightly (WMD: - 3.03, 95% CI: - 3.42, - 2.64) in an intratesticular injection of low-dose busulfan (4 - 6 mg/kg), and the model almost returned to normal after one seminiferous cycle.
The model using low-dose busulfan (10 - 20 mg/kg) returned to normal after 10 - 15 weeks. However, in some spermatogenesis cycles, testicular weight reduction and testicular spermatogenic function damage were not proportional to busulfan dose. Sperm counts and motility results in different studies had significant heterogeneity. Standard protocols for sperm assessment in animal models were needed to reduce heterogeneity between studies.
关于白消安诱导少弱精子症的建模方法存在争议。本研究旨在系统综述白消安诱导少弱精子症的建模方法,并分析不同白消安剂量随时间变化时各项评估指标的变化。
我们检索了 Cochrane 图书馆、PubMed 数据库、Web of Science、中国知网和中国生物医学文献服务系统,检索时间截至 2022 年 4 月 9 日。纳入白消安诱导精子发生功能障碍的动物实验,并进行筛选。对模型死亡率和评估指标的参数进行荟萃分析。
共纳入 29 项动物研究(对照组/模型组:669/1829)。随着白消安剂量的增加,小鼠的死亡率增加。无论白消安剂量(10-40mg/kg)如何,5 周内都会发生明显的生精功能障碍(WMD:-0.04,95%CI:-0.05,-0.03)。睾丸重量(WMD:-0.04,95%CI:-0.05,-0.03)、睾丸指数(WMD:-2.10,95%CI:-2.43,-1.76)和 Johnsen 评分(WMD:-4.67,95%CI:-5.99,-3.35)均显著降低。模型组精子计数减少了 32.8×10/ml(WMD:-32.8,95%CI:-44.34,-21.28),精子活力降低了 37%(WMD:-0.37,95%CI:-0.47,-0.27)。低剂量白消安(4-6mg/kg)睾丸内注射后精子计数略有减少(WMD:-3.03,95%CI:-3.42,-2.64),一个生精周期后模型基本恢复正常。
使用低剂量白消安(10-20mg/kg)的模型在 10-15 周后恢复正常。然而,在某些生精周期中,睾丸重量减轻和睾丸生精功能损伤与白消安剂量不成比例。不同研究中精子计数和活力结果的异质性显著。需要动物模型精子评估的标准方案来减少研究间的异质性。